Tumor
Conditions
Sponsors
Chongqing University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18 to 80 years old (including 18 and 80 years old), gender not restricted; 2. Confirmed tumor, currently undergoing or planning to receive chemotherapy/radiotherapy/targeted therapy/immunotherapy; 3. Normal baseline echocardiogram and electrocardiogram; 4. No history of heart disease (including but not limited to myocarditis, myocardial infarction, myocardial ischemia, congestive heart failure, coronary artery disease); no diabetes; 5. Expected survival period >= 12 weeks; 6. Baseline blood routine, coagulation and liver and kidney function test results meet the following standards. Blood routine: WBC >= 4.0×10^9/L or neutrophils >= 1.5×10^9/L, PLT >= 100×10^9/L, Hb >= 90 g/L; PT or APTT <= 1.5 ULN. Liver and kidney function: T-Bil <= 1.5×ULT (upper limit of normal), ALT/AST <= 2.5 ULN or <= 5×ULT (for subjects with liver metastasis), ALP <= 2.5 ULN (if bone or liver metastasis exists, ALP <= 4.5 ULN); BUN <= 1.5×ULT, SCr <= 1.5×ULT; Troponin (CTnT/I), B-type natriuretic peptide (BNP), N-terminal B-type natriuretic peptide (NT-proBNP) normal; 7. Women must use effective contraceptive measures during the study and within 6 months after the study (effective contraceptive measures refer to sterilization, intrauterine hormonal devices, condoms, contraceptive pills/pills, abstinence or partner's vasectomy, etc.); men should agree to use contraceptive measures during the study and within 6 months after the study; 8. Those who can understand and voluntarily sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1. Baseline echocardiogram shows LVEF less than 50%; 2. Has other malignant tumors; 3. Has history of heart or brain diseases or related surgeries history of chest radiotherapy; 4. Pregnant women, lactating women or those planning pregnancy; 5. Those who are allergic to radioactive probe components or contrast agent (gadopentetate dimeglumine), diabetics taking metformin, and participants with kidney diseases; those with serum creatinine level > 2.0 mg/dl; those who cannot lie flat for 1-1.5 hours; those undergoing PET/MR examination who need to exclude any fixed metal in the body; 6. Those with a history of substance abuse of psychotropic drugs and unable to quit or with mental disorders, those who cannot sign the informed consent or complete the follow-up (such as aphasia, dementia); 7. Those whose fasting blood glucose level before injection of FDG exceeds 11.1 mmol/L; 8. Those who have participated in other interventional clinical trials within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PET parameters (such as SUVmax, MTV, TLG, etc.);The signals of each sequence in cardiac MR, cardiac function parameters (LVEF, EDV, ESV, myocardial strain, etc.), and the degree and range of delayed enhancement in cardiac MR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Simple Mental State Examination Scale, Pittsburgh Sleep Quality Index Form, FACT-G Quality of Life Measurement Scale, Depression Assessment Scale;Laboratory examination indicators (myocardial enzyme spectrum, etc.), echocardiography, electrocardiogram, etc; | — |
Countries
China
Contacts
Public ContactXiaoliang Chen
Chongqing University Cancer Hospital
Outcome results
None listed